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The interface between the HIV-1 gp120 envelope
glycoprotein and the CD4 receptor contains an
unusual interfacial cavity, the ‘‘Phe43 cavity’’, which
CD4-mimetic miniproteins with nonnatural exten-
sions can potentially utilize to enhance their neutral-
ization of HIV-1. Here, we report cocrystal structures
of HIV-1 gp120 with miniproteins M48U1 andM48U7,
which insert cyclohexylmethoxy and 5-hydroxypen-
tylmethoxy extensions, respectively, into the Phe43
cavity. Both inserts displayed flexibility and hydro-
phobic interactions, but the M48U1 insert showed
better shape complementarity with the Phe43 cavity
than the M48U7 insert. Subtle alteration in the gp120
conformation played a substantial role in optimizing
fit. With M48U1, these translated into a YU2-gp120
affinity of 0.015 nM and neutralization of all 180
circulating HIV-1 strains tested, except clade-A/E
isolates with noncanonical Phe43 cavities. Ligand
chemistry, shape complementarity, surface burial,
and gp120 conformation act in concert to modulate
binding of ligands to the gp120-Phe43 cavity and,
when optimized, can effect near-pan-neutralization
of HIV-1.
INTRODUCTION
The gp120 envelope glycoprotein of the human immunodefi-
ciency virus type 1 (HIV-1) is conformationally flexible and un-
dergoes substantial structural rearrangements during HIV-1
entry into cells (Guttman et al., 2012; Myszka et al., 2000; Wyatt
et al., 1998). gp120 consists of several autonomously folded
domains, namely, the outer domain, the inner domain, the
bridging sheet, and the V1/V2 region, and these domains may
adopt different relative spatial arrangements in response to
ligand binding or oligomeric interactions within the functional
viral spike (Chen et al., 2005, 2009; McLellan et al., 2011; Pan-
cera et al., 2010; Zhou et al., 2007). In the conformation of
gp120 induced by engagement of the CD4 receptor, an interfa-
cial cavity forms at the nexus of the inner domain, the outer1018 Structure 21, 1018–1029, June 4, 2013 ª2013 Elsevier Ltd All ridomain, the bridging sheet, and the CD4 receptor (Kwong
et al., 1998). This interfacial cavity, called the ‘‘Phe43 cavity’’,
is capped on one end by the phenyl ring of residue 43CD4 and
bordered by conserved gp120 residues, and its volume is
150 A˚3 (for clarity, residue numbers are subscript labeled
with the macromolecule of which they are a part).
Natural amino acids cannot fully access the Phe43 cavity,
which extends 8 A˚ beyond the phenyl ring of residue 43CD4
(Kwong et al., 1998). Synthetic chemistry offers the opportunity
to interact fully with this cavity via nonnatural, cavity-filling
ligands (Curreli et al., 2012; Huang et al., 2005; Lalonde et al.,
2011, 2012; Stricher et al., 2008). One such synthetic system
was developed by transplanting critical elements of the gp120-
interactive region of CD4 to a structurally compatible scyllatoxin
scaffold (Vita et al., 1999). Structure-guided optimizations of the
miniprotein backbone (Martin et al., 2003; Stricher et al., 2008),
as well as the side chain of residue 23miniprotein, which is located
in a position analogous to that of residue 43CD4 (Huang et al.,
2005), resulted in M48 and M47, both with nanomolar affinity
for gp120 (Stricher et al., 2008). M48 contains a Phe at position
23M48 (Table 1), whereas M47 inserts a biphenylalanine 5 A˚
into the Phe43 cavity. The structure of gp120 bound to M48
(Stricher et al., 2008) closely resembled the structure of gp120
bound to CD4, both in overall conformation and in the region
near the Phe43 cavity. In the M47-bound gp120 structure, inser-
tion of a rigid biphenyl appeared to distort the gp120 conforma-
tion in the region surrounding the insertion (Stricher et al., 2008).
This observation spurred the design of CD4-mimetic miniprotein
variants with flexible inserts that extend into the Phe43 cavity
(Van Herrewege et al., 2008).
One of these variants, M48U1, contained a cyclohexylme-
thoxy phenylalanine at position 23M48U1 and displayed remark-
ably potent neutralization of three HIV-1 isolates (Van Herrewege
et al., 2008), and a recent study demonstrated its efficacy as a
microbicide (Dereuddre-Bosquet et al., 2012). To determine
the structural basis for the potent antiviral activity of M48U1,
we determined its crystal structure in complex with HIV-1
gp120. For comparison, we also determined the structure of
M48U7, which contained a 5-hydroxypentylmethoxy phenylala-
nine at residue 23M48U7. Structural, biochemical, and virological
analyses of M48U1 and M48U7, as well as those of the previ-
ously reported miniproteins M48 and M47, helped to elucidate
the structural basis for potent neutralization at the Phe43 cavity
of gp120.ghts reserved
Table 1. CD4 and CD4-Mimetic Miniproteins: Sequences, Phe43 Cavity Inserts, YU2 gp120 Affinity, and X-Ray Crystal Structures with
HIV-1 gp120
Sequence Phe43 Cavity Insert KD to YU2 gp120 (nM)
Structural Resolution
of gp120 Complex (A˚)
CD4 22-..KSIQFHWKNSNQIKILGNQGS F LTK....-47 7.68 ± 0.33 (Stricher et al., 2008) 2.9 (Kwong et al., 2000)
M48 1-TpaNLHFCQLRCKSLGLLGRCAdPT F CACVNH2 3.87 ± 0.10 (Stricher et al., 2008) 2.4 (Stricher et al., 2008)
M47 1-TpaNLHFCQLRCKSLGLLGRCAdPTBipCACVNH2 2.12 ± 0.05 (Stricher et al., 2008) 2.2 (Stricher et al., 2008)
M48U1 1-TpaNLHFCQLRCKSLGLLGRCAdPT U1CACVNH2 0.0154 ± 0.0008 (this study) 1.5 (this study)
M48U7 1-TpaNLHFCQLRCKSLGLLGRCAdPT U7CACVNH2 0.18 ± 0.03 (this study) 2.1 (this study)
Tpa, thiopropionic acid; dP, D-proline; Bip, biphenylalanine; U1, cyclohexylmethoxy phenylalanine; U7, hydroxypentylmethoxy phenylalanine.
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Surface Plasmon Resonance Analysis of M48U1 and
M48U7
To place the neutralization properties of M48U1 into a biochem-
ical context, we used surface plasmon resonance to determine
the binding affinity of M48U1 for YU2 gp120 (Figure 1A; Table 1;
Table S1 available online). With gp120 immoblized on a
CM5 chip, we observed an extraordinary affinity of 0.0154 ±
0.0008 nM (Figure 1A; Table 1), and association and dissociation
rates of 2.533 106M1 s1 and 3.93 105 s1, respectively (Fig-
ure 1A; Table S1). To verify affinity, we reversed the experimental
format by coupling M48U1 to a CM5 chip via Lys11M48U1. A
binding affinity of 0.014 ± 0.005 nM was observed (Figure S1),
comparable to the affinity obtained with gp120 immobilized.
gp120 affinity for the closely related CD4-mimetic miniprotein,
M48U7, was 0.18 ± 0.03 nM (Figure 1B), with an association
rate of 2.42 3 106 M1 s1 and an off rate of 4.46 3 104 s1.
For comparison, sCD4 and the CD4-mimetic miniproteins, M48
and M47, have gp120 binding affinities of 7.7 nM, 4.0 nM, and
2.1 nM, respectively (Stricher et al., 2008). Thus, M48U1 dis-
played more than 100-fold tighter binding to YU2 gp120
compared to sCD4 and previously characterized CD4-mimetic
miniproteins, and 10-fold tighter binding compared to M48U7
(Table 1; Table S1). The remarkable affinity of M48U1 for
gp120 was contributed by both its higher rate of association
with gp120 and its slower dissociation rate. Although M48U1
and M48U7 both showed tighter affinities to gp120 compared
to sCD4, M48, andM47, the discriminating factor between these
two miniproteins was their off rates, with M48U1 dissociating
from gp120 about 10 times slower than did M48U7.
Crystal Structures of gp120 Bound to CD4-Mimetic
Miniproteins
To gain structural information on the gp120 interactions of
M48U1 and M48U7, we crystallized the miniproteins in complex
with a truncated version of YU2 gp120 (YU2coree) (Kwon et al.,
2012). Complexes crystallized as plates in two related spaceStructure 21, 10groups, P212121 and C2221 (Table 2). For M48U1, the C2221
crystal form contained one complex in the asymmetric unit and
diffracted to 1.49 A˚, and the P212121 crystal form contained
two molecules in the asymmetric unit and diffracted to 1.8 A˚.
M48U7 crystallized in the C2221 crystal form and diffracted to
2.1 A˚. Unless otherwise noted, the C2221 crystal forms of each
complex were used for structural comparisons.
Structures were solved by molecular replacement using
gp120-M48 coordinates from Protein Data Bank [PDB] ID 2I60
(Stricher et al., 2008) as a search model. Unoccupied density
was visible in the Phe43 cavity, into which either U1 or U7 inserts
were built. Multiple cycles of simulated annealing, TLS, ADP,
positional refinement, and automated water picking were
employed, and these were alternated with manual model build-
ing to obtain final Rfree/Rwork values of 22.3%/18.2% and
18.5%/16.5% for gp120-M48U1 structures in space groups
P212121 and C2221, respectively, and 21.9%/18.0%, for the
gp120-M48U7 structure (Table 2).
M48U1 and M48U7 bound at the gp120 CD4-binding site, at
the intersection of three gp120 domains (Figures 2A and 2B).
The observed gp120 conformations in the M48U1 and M48U7
bound states were similar to each other, with an overall Ca
rmsd of 0.31 A˚, and within the range of variation observed for
CD4 and other CD4-mimetic miniproteins (Huang et al., 2005;
Stricher et al., 2008).
CD4-Mimetic Features in M48U1 and M48U7 Cocrystal
Structures
As a first step toward understanding the structure-function rela-
tionship of the CD4-mimetic miniproteins, we compared the
structural mimicry of their gp120 recognition with that of CD4.
Specifically, we compared gp120-M48U1 and gp120-M48U7
structures to CD4-bound gp120 structures, as well as to gp120
bound to CD4-binding-site antibodies like VRC01 that bind the
CD4-bound conformation of gp120 and others such as b12,
b13, and F105, which have been shown to induce non-CD4-
bound conformations of gp120 (Figure S2). Overall, the confor-
mation of gp120 core bound to M48U1 or M48U7 appeared18–1029, June 4, 2013 ª2013 Elsevier Ltd All rights reserved 1019
Figure 1. Surface-Plasmon-Resonance Analysis of the Binding of
CD4-Mimetic Miniproteins M48U1 and M48U7 to HIV-1 YU2 gp120
A very slow dissociation rate contributes to the extraordinary affinity of M48U1
for gp120. M48U7 binds with a similar on-rate but dissociates from gp120
about 10-times faster thanM48U1. Surface-plasmon-resonance profiles of the
binding of M48U1 (A) and M48U7 (B) to full-length HIV-1 gp120 from the clade
B YU2 strain. The black lines indicate independent injections of the CD4-
mimetic miniproteins with concentrations sampled at 2-fold dilution. Con-
centrations from 3 nM to 0.006 nM and from 8 nM to 0.06 nMwere sampled for
M48U1 and M48U7, respectively. Each concentration was sampled in dupli-
cate. The red lines show the global fit of the data to a Langmuir 1:1 binding
model. A surface-plasmon-resonance profile of HIV-1 YU2 gp120 binding to
M48U1 immobilized on a CM5 chip is shown in Figure S1. Binding affinities are
listed with their standard errors.
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Cocrystal Structure of HIV-1 gp120 with M48U1similar to the CD4-bound conformation of core gp120 (Figures
2A and 2B), with main-chain rmsds of 0.73 and 0.82, respec-
tively, in relation to CD4-bound gp120 (PDB ID 1RZK), and
differed from other structurally characterized non-CD4-bound
gp120 conformations (b12-bound, b13-bound, F105-bound,
and unliganded SIV conformation) (Chen et al., 2005, 2009;
Zhou et al., 2007). The exposed edge of the C-terminal b strand
of M48U1 and M48U7 forms a hydrogen bond with the b15-
strand of gp120 in an antiparallel manner similar to that observed
for the CDR2-like loop of CD4 (Figures 2C and 2E). Both mini-
proteins use Arg9miniprotein to engage the highly conserved
Asp368gp120 in a salt bridge interaction reminiscent of the inter-
action CD4makes via its Arg59CD4 (Kwong et al., 1998). A critical
interaction at the gp120-CD4 interface is made by the Phe43CD4
side chain, which caps the mouth of the Phe43 cavity. This
phenyl interaction is preserved with each of the CD4-mimetic
miniproteins (Table 1; Figures 2C–2F) (Huang et al., 2005;
Stricher et al., 2008) via residue 23miniprotein, which is a Phe in
M48 and a Phe-derivative in the other miniproteins. Thus, like
the CD4-mimetic miniproteins previously described (Huang
et al., 2005; Stricher et al., 2008), M48U1 and M48U7 mimic crit-
ical structural elements of CD4 recognition of gp120, including
an intermolecular antiparallel b-strand interaction with the b15-
strand of gp120, a salt bridge with Asp368gp120, and insertion
of a phenyl cap at the mouth of the gp120 Phe43 cavity.
Interactions of M48U1 and M48U7 within the Phe43
Pocket
The only chemical difference between the miniproteins was in
their Phe43-cavity inserts (Table 1). Analysis of the miniprotein
interface with gp120 showed that interactions outside the
Phe43 cavity were overall similar in the different miniprotein
complexes (Table S2), with variation between the different mini-
proteins equivalent to the variation between different complexes
of the same miniprotein. This led us to reason that the remark-1020 Structure 21, 1018–1029, June 4, 2013 ª2013 Elsevier Ltd All riable gp120-binding and neutralization properties of M48U1,
and its differences from the other miniproteins, were likely
related to their Phe43-cavity interactions. We therefore focused
our attention on the Phe43 cavity and sought to understand the
details of its interaction with residue 23miniprotein, which pene-
trates the cavity.
With a phenyl capping the mouth of the Phe43 cavity, the
cyclohexylmethoxy (U1) in M48U1 and the 5-hydroxypentylme-
thoxy (U7) in M48U7 extended 6.5 A˚ and 6.2 A˚, respectively,
into the Phe43 cavity (Figures 2D and 2F). The Phe43 cavity is
predominantly nonpolar, with islands of polarity contributed
by (1) polar atoms from residues lining the cavity walls (main-
chain O atoms of Ser375gp120, Val255gp120, Phe376gp120, and
Asn425gp120; main-chain N atoms of Ser256gp120, Phe376gp120,
and Asn377gp120; and side-chain O atoms of Ser375gp120 and
Tyr384gp120); (2) a conserved solvent channel 6.2 A˚ from the
cavity mouth; and (3) an opening at the interior apex of the cavity
capped by a water molecule (W1) (Figure 3).
U1 is predominantly nonpolar and makes hydrophobic inter-
actions with residues lining the Phe43-cavity walls. The only
polar region on U1 is its ether oxygen, which is oriented toward
the gp120 solvent channel. The observed distance between
the ether oxygen and the nearest water of the solvent channel
is 3.6 A˚ in all three asymmetric units, slightly beyond standard
hydrogen-bonding distance. The cyclohexyl group fills the inner
recess of the Phe43 cavity, interacting with Phe382gp120,
Trp112gp120, and Val255gp120, which form a hydrophobic cluster
at the cavity ceiling (Figures 3A–3D).
U7 is an alkyl alcohol with greater conformational freedom
compared to U1. U7 accommodates its terminal hydroxyl group
in a predominantly hydrophobic pocket by directing the hydroxyl
away from hydrophobic regions and orienting it toward polar re-
gions of the Phe43 cavity. Whereas the alkyl chain interacts with
the hydrophobic walls of the Phe43 cavity, the hydroxyl moiety
appears in two distinct conformations, one hydrogen bonding
with the Ser375gp120 hydroxyl group and the other with the
gp120 solvent channel (Figure 3B).
M48U1 and M48U7 are two examples of how Phe43-cavity-
penetrating ligands can utilize different chemistries and confor-
mations to interact with this cavity. In summary, the U1 moiety
in M48U1 makes 11 hydrophobic interactions with gp120, and
the U7 moiety in M48U7 makes eight hydrophobic interactions
and one hydrogen-bond interaction in each of its two conforma-
tions, showing an overall qualitative similarity between the
number of contacts that the two inserts make with the Phe43
cavity.
Residual Flexibility of U1 and U7 in Their Bound States
While X-ray crystal structures principally offer static snapshots of
macromolecular states, information on relative flexibility, disor-
der, and movement can sometimes be gleaned from features
presented by electron density maps. The residue 23M48U7 phenyl
ring shows a well-defined electron density (Figure 2F), whereas
its alkyl chain shows two distinct conformations, with the termi-
nal hydroxyl in each conformation oriented toward a polar region
in the Phe43 cavity.
The electron density of gp120-bound U1 also revealed resid-
ual flexibility (Figure 2D). The U1-cyclohexane ring showed
asymmetric electron density, with some regions showingghts reserved
Table 2. Crystallographic Data Collection and Refinement
Statistics
PDB Accession Code 4JZW 4JZZ 4K0A
Complex
CD4-mimetic
miniprotein
M48U1 M48U1 M48U7
gp120 YU2 gp120
coree
YU2 gp120
coree
YU2 gp120
coree
Data Collection
Space group P212121 C2221 C2221
Cell Constants
a, b, c (A˚) 63.65, 78.01,
163.25
65.09, 164.72,
78.03
65.52, 164.66,
78.00
a, b, g () 90.0, 90.0,
90.0
90.0, 90.0,
90.0
90.0, 90.0,
90.0
Wavelength (A˚) 1 1 1
Resolution (A˚) 50.0–1.8
(1.86–1.8)
50.0–1.49
(1.52–1.49)
50.0–2.10
(2.14–2.10)
Rsym
a 9.2 (43.8) 11.7 (58.5) 18.0(60.7)
I/sI 22.9 (2.2) 20.5 (2.1) 8.7(1.3)
Completeness (%) 83.7 (74.7) 99.3 (93) 90.6(61.1)
Redundancy 4.1 (2.9) 7.6 (3.5) 5.4(2.3)
Refinement
Resolution (A˚) 24.66–1.78
(1.81–1.78)
35.3–1.49
(1.51–1.49)
36.41–2.13
(2.22–2.13)
Unique reflections 64634 (1672) 67986(2445) 21349(1464)
Rwork / Rfree (%)
b 0.182/0.223 0.165/0.185 0.180/0.219
No. of atoms
Protein 6,162 3,129 3,068
Sugar (NAG) 238 140 112
M48U1/U7 463 252 234
U1/U7 38 35 24
Ligand/ion 32 38 29
Water 929 372 151
B-Factors (A˚2)
Overall 36.86 30.43 39.45
Protein 33.91 27.56 42.11
Sugars (NAG) 58.63 45.08 62.87
M48U1/M48U7 45.29 42.76 64.58
U1/U7 26.01 20.02 34.10
Ligand/ion 55.41 54.28 77.4
Water 45.58 38.32 42.55
Rmsds
Bond lengths (A˚) 0.007 0.009 0.003
Bond angles () 1.054 1.365 0.861
Chiral volume (A˚2) 0.061 0.073 0.044
Estimated coordinate
error (maximum
likelihood esu) (A˚)
0.19 0.14 0.26
Table 2. Continued
PDB Accession Code 4JZW 4JZZ 4K0A
Ramachandran
Favored regions (%) 98 98 98
Additional allowed
regions (%)
2 2 2
Disallowed regions (%) 0 0 0
Values in parentheses are for the highest-resolution shell. Rfree is
calculated from 5% of the reflections excluded from refinement.
aRsym = SjI  hIi j/S hIi, where I is the observed intensity, and hIi is
the average intensity of multiple observations of symmetry-related
reflections.
bR = ShkljjFobsj  jFcalcjj/ShkljFobsj.
Structure
Cocrystal Structure of HIV-1 gp120 with M48U1well-defined electron density and other regions showing poorly
defined electron density, the latter suggestive of multiple confor-
mations unconstrained by interactions with the Phe43 cavity.
The methoxy cyclohexyl moiety in the C2221 crystal form wasStructure 21, 10more disordered than the complexes in the P212121 crystal
form and was modeled as two alternate conformations. For
clarity, the predominant conformation found in both molecules
in the asymmetric unit of the P212121 crystal form, as well as
the C2221 crystal form, is shown in the figures. In contrast, the
U1 phenyl ring shows symmetric and continuous electron
density suggestive of a defined structure, constrained by its
interactions with gp120. This is similar to the well-defined elec-
tron densities observed for Phe43CD4 in CD4-bound gp120
structures, for Phe23M48 in the M48-bound gp120 structure,
and for the less buried phenyl ring in Bip23 in the M47-bound
gp120 structure (Kwong et al., 1998; Stricher et al., 2008).
The residual flexibility of U1 in its bound statemay play a role in
the remarkable neutralization properties of M48U1 by allowing
the insert to adapt to changes in the Phe43 cavity conformation
as a result of strain-to-strain variation (Shrivastava and LaLonde,
2011). A similar beneficial effect of inhibitor flexibility has been
shown for HIV-1 proteases, where flexible inhibitors better resist
active-site variations and suffer less entropic penalty compared
to rigid inhibitors (Vega et al., 2004).
M48U1 and M48U7 are two examples of ligands utilizing their
flexibility to maximize interactions and avoid potential clashes in
protein-binding sites. Although U1 andU7moieties are both flex-
ible, and both retain mobility in their bound states, M48U1 and
M48U7 differ substantially in their gp120 binding affinities and
HIV-1 neutralization potencies. This suggests that not only is
ligand flexibility important, but the precise shape or geometry
of the ligand may also contribute to its binding affinity to the
Phe43 cavity.
Shape Complementarity and Surface Burial of the
CD4-Mimetic Miniproteins at the gp120 Phe43 Cavity
To estimate the goodness of fit of each miniprotein insert to the
Phe43 cavity, we calculated the shape complementarity (SC)
(Lawrence and Colman, 1993) of the insert to the binding pocket,
as well as its buried surface area (Krissinel and Henrick, 2007)
(Table 3). SC measures the geometric surface complementarity
of interfaces and depends both on the relative shape of the sur-
faces and the extent to which the interaction brings individual
elements of the opposing surfaces into proximity. We calculated
SC for Phe43 cavity inserts fromCD4 and the CD4-mimetic mini-
proteins M48, M47, M48U1, and M48U7 (Table 3). Phe43CD4, a
natural Phe43-cavity ligand, showed the highest SC statistic,
indicating the best shape complementarity. SC of Phe23M4818–1029, June 4, 2013 ª2013 Elsevier Ltd All rights reserved 1021
Figure 2. Structures of M48U1 and M48U7
Bound to HIV-1 gp120 Show Ligand Inserts
Penetrating and Filling the gp120 Phe43
Cavity
(A) M48U1 (red and green) binds to a conserved
gp120 cavity at the intersection of the outer
domain (wheat), inner domain (slate), and bridging
sheet (pink).
(B) M48U7 (red and cyan) binds to the same site on
gp120 asM48U1. gp120 is shownas agray surface
with the CD4 footprint on gp120 colored yellow.
(C) Zoomed-in view of the M48U1 binding site
showing hydrogen bonding (black dotted lines) of
M48U1 Arg 9 with the conserved Asp 368 of
gp120. (A) and (C) are related by an approximately
90 rotation about a horizontal axis.
(D) gp120 cross-section showing the U1 side
chain (green sticks with the oxygen atom colored
red) penetrating the Phe43 cavity. (A) and (D) are
related by an approximately 90 rotation about a
vertical axis.
(E) Zoomed-in view of the M48U7 binding site
showing the salt bridge (black dotted line) of
M48U7 Arg9 with gp120 Asp368. (B) and (E) are
related by an approximately 90 rotation about a
horizontal axis.
(F) gp120 cross-section showing the U7 side chain (cyan sticks with the oxygen atom colored red) penetrating the Phe43 cavity. The blue mesh represents
the 2Fo  Fc map contoured at 2s for M48U1 and 1.6s for M48U7. (B) and (F) are related by an approximately 90 rotation about a vertical axis.
See also Figure S2.
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Cocrystal Structure of HIV-1 gp120 with M48U1matched closely with that of Phe43CD4, consistent with pub-
lished reports that show M48 to be a close structural mimic of
CD4 (Stricher et al., 2008). Of the other three CD4-mimetic mini-
proteins (Table 1), M48U1 had the highest SC (Table 3) of 0.762,
followed by M47, and M48U7 showed the lowest SC of 0.703.
These results revealed that nonnatural excursions into the
Phe43 cavity resulted in reduced overall shape complementarity
compared to the fit of the natural phenyl, and that of these
nonnatural excursions, U1 showed the best shape complemen-
tarity (Figures 3E and 3F; Table 3).
The extent of surface burial is another determinant of intermo-
lecular interaction, with a larger shared interfacial area between
two molecules suggesting more interfacial contacts and better
binding. We calculated buried surface areas for all the Phe43-
cavity inserts (Table 1). As expected CD4 and M48 showed the
least surface burial (Table 3) since they have the smallest
Phe43-cavity insert. Phe43CD4 and Phe23M48 bind the Phe43-
cavity mouth, leaving the rest of the cavity unoccupied. M48U1
and M48U7 showed the highest surface burial, followed by M47.
Shape complementarity and surface burial are two indepen-
dent parameters, with shape complementarity being a measure
of local fit of the two binding partners and surface burial a
measure of their total interfacial area. Since both parameters
contribute to overall fit, we empirically derived a combined fit
parameter by multiplying SC by the buried surface area for each
pair of interactions (Table 3). This combined fit parameter showed
that M48U1 had the best overall fit to the Phe43 cavity, followed
by M48U7, M47, and M48 in decreasing order of overall fit.
Structural Changes in gp120 Related to Ligand Insertion
into the Phe43 Cavity
We next sought to understand Phe43 cavity conformational
changes in response to ligand binding. Although overall the1022 Structure 21, 1018–1029, June 4, 2013 ª2013 Elsevier Ltd All riconformation of gp120 coree bound to M48U1 or M48U7 resem-
bled the CD4-bound conformation (Figures 2A and 2B; Fig-
ure S2), local conformational changes in the vicinity of the bound
ligand may affect ligand fit and influence binding affinity. To un-
derstand the effect of ligand insertion on the conformation of the
Phe43 cavity, we analyzed gp120 conformational changes in the
vicinity of the U1 or U7 insertion.
For precise definition of the cavity, we used the algorithm
fpocket (Le Guilloux et al., 2009). The highest-scoring pocket
was a 505 A˚3 space made up of two intersecting regions—the
Phe43 cavity and a conserved gp120 solvent channel (Figures
2 and 3; Figure S3). This bifurcated cavity is made up of residues
from the bridging sheet, the a1 and a3 (commonly known as the
CD4 binding loop) helices, and loop B. A conserved solvent
channel starts from an opening in the Phe43 cavity, about
6.2 A˚ from the cavity mouth, and connects the gp120 CD4
binding site to the coreceptor binding site (Figures 3A and 3D;
Figure S3).
U1 and U7 bind to the Phe43 cavity, extending into the
gp120 hydrophobic core, thereby filling a region of topological
mismatch in gp120’s hydrophobic interior (Figures 2 and 3). To
study local effects of ligand binding, we first calculated Phe43-
cavity volume in each of the complexes in the absence of ligand
(Figure S4). The calculated volumes were overall similar between
the miniprotein complexes. We then analyzed ligand-induced
changes in the Phe43 cavity at the residue level by constructing
distance-sorted difference distance matrices (Huang et al.,
2005). This structural analysis technique was earlier used to
study gp120 conformational changes on binding to M48 and
M47 (Huang et al., 2005; Stricher et al., 2008). Difference dis-
tance matrices allow superposition-independent and residue-
specific structural comparison, and overall summations are
obtained by calculating the rms of matrix elements.ghts reserved
Figure 3. Interactions of M48U1 and M48U7
with the gp120 Phe43 Cavity
Flexible inserts use shape and chemical comple-
mentarity to optimize fit to the Phe43 cavity.
(A) M48U1 (red and green) binds to a conserved
gp120 cavity at the intersection of the outer domain
(wheat), inner domain (slate), and bridging sheet
(pink). Red spheres are water molecules.
(B) M48U7 (red and cyan) binds to the same site on
gp120 as M48U1. gp120 is shown in gray cartoon
representation, with the residues lining the Phe43
cavity shown as sticks, and nitrogen atoms colored
blue and oxygen atoms colored red. The black
dotted lines show hydrogen bonds made by the
terminal hydroxyl group of the residue 23M48U7 side
chain in the Phe43 cavity.
(C and D) Views of (A) and (B), respectively,
rotated 90.
(E) Zoomed-in view of the U1 moiety inserting into
the Phe43 cavity.
(F) Zoomed-in view of the U7 moiety inserting into
the Phe43 cavity. The CD4-binding footprint is
colored yellow. In the multilayer transparent sur-
face representation shown in (E) and (F), the outer
surface is gp120 and the inner surface is the ligand.
Interactions of M48U1 and M48U7 outside the
Phe43 cavity are shown in Table S2.
Structure
Cocrystal Structure of HIV-1 gp120 with M48U1A distance-sorted double sieve was used to derive the subset
of atoms for difference-distance-matrix calculations. First,
atoms lining the cavity were selected using the program fpocket.
Next, atoms from this subset that were%6A˚ from M48U1 were
selected. Finally, these atoms were sorted by their distance
from the 23M48U1 Ca atom. The Ser375 side-chain hydroxyl
and Ile424 CG1 were found at different positions in various
CD4- and mimetic-bound structures as a result of stochastic
rotameric variation, and were therefore disregarded for the
analysis. Figure 4 tabulates the set of atoms used for this
analysis.Structure 21, 1018–1029, June 4, 2013 ªWe first analyzed differences in the
Phe43 cavity between unliganded YU2
core gp120 (PDB ID 3TGQ) and YU2
core gp120 bound to CD4 and 17b, a
CD4-induced (CD4i) antibody that stabi-
lizes the CD4-bound conformation (PDB
ID 1RZK), by constructing difference dis-
tance matrices. We detected CD4-bind-
ing-induced movement in the gp120
Phe43 cavity (Figures 4 and 5A). The
largest conformational perturbations
were found, as expected, closest to the
region of Phe43CD4 insertion in gp120,
with changes progressively decreasing
in magnitude at increasing distances
from the region of Phe43CD4 insertion. It
is pertinent to note that the net relative
change on CD4 binding suggests overall
contraction of the Phe43 pocket, espe-
cially surrounding the region of Phe43CD4
insertion. This qualitatively represents a
transition from a relaxed state of thegp120 domains to a state constrained by Phe43CD4 insertion at
the mouth of the Phe43 cavity, with the gp120 domains brought
closer by their interaction with Phe43CD4.
We comparedM48U1-bound andM48U7-bound gp120 to un-
liganded (Kwon et al., 2012) and CD4-bound core gp120 (Kwong
et al., 1998) (Figures 4 and 5B–5E), and found that the Phe43 cav-
ity, when bound to these CD4 mimetics, showed greater resem-
blance to the Phe43 cavity in unliganded core gp120 (gp120
coree) than to that in CD4-bound gp120. This finding is consistent
with thepropensityof thePhe43cavity tobefilled, as inferred from
crystal structures that show small molecules from crystallization2013 Elsevier Ltd All rights reserved 1023
Table 3. Structural Properties and Biological Activity of CD4 and CD4-Mimetic Miniproteins
SC (in Phe43
Cavity)
BSA (in Phe43
Cavity) (A˚2) [SC] 3 [BSA]
Mean Difference Distancesa
versus Unliganded HIV-1
gp120 Phe43 Cavity
Neutralization Potency in mg/ml
(Breadth in %)
24-Isolate Panel 180-Isolate Panel
CD4 0.823 196 161 0.29 3.7 (79.0) 3.4 (79.2)
M48 0.822 196 161 0.28 5.4 (62.5) 2.1 (70.2)
M47 0.735 310 228 0.33 5.0 (70.8) 2.3 (76.2)
M48U1 0.762 353 269 0.21 0.39 (83.0) 0.13 (90.4)
M48U7 0.703 352 247 0.20 5.2 (63.0) ND
Numbers in parentheses indicate the breadth percentage. SC, shape complementarity; BSA, buried surface area; ND, not determined.
aMean difference distances shown in Figures 4 and 5.
Structure
Cocrystal Structure of HIV-1 gp120 with M48U1solutions occupying the Phe43 cavity (Figure S4), and suggests
that cavity filling leads to stabilizationof thePhe43cavity.Residue
23M48U1/M48U7 insertions fill the Phe43 cavity, thereby stabilizing
its relaxed or ground state by counteracting the partial ‘‘Phe43-
cavitycollapse’’ inducedbyCD4binding.Wealsoobserved local-
ized movement in the Phe43 cavity in response to U1 and U7
insertion. These changes were most dominant at the deeper
end of the Phe43 cavity, and in the case of U1, involved residues1024 Structure 21, 1018–1029, June 4, 2013 ª2013 Elsevier Ltd All riPhe382gp120, Trp112gp120, and Val255gp120 which form a hydro-
phobic/aromatic cluster near the ceiling of the cavity, and
Ile424gp120 (Figures 3A, 3C, 4, and 5).
We expanded this analysis to CD4-mimetic miniproteins M48
andM47 (Stricher et al., 2008) (Figure 6). We found that the M48-
bound Phe43 cavity resembled the CD4-bound cavity more than
the unliganded core gp120 cavity. Binding to M47 distorted
the Phe43 cavity more than any of the other CD4-mimeticFigure 4. Distance-Sorted Difference Dis-
tance Matrices Reveal Conformational
Changes in the gp120 Phe43 Cavity as a
Result of M48U1 and M48U7 Binding
gp120 Phe43 cavity bound to M48U1 or M48U7
shows greater resemblance to the Phe43 cavity in
unliganded gp120 than to the Phe43 cavity in
gp120 bound to CD4 and CD4-induced mono-
clonal antibody 17b. Distance-sorted difference
distance matrices of gp120 were constructed
using coordinates of atoms lining the gp120 Phe
43 cavity selected with fpocket. Atoms within 6 A˚
of U1 were sorted in increasing order of distance
from the Phe43 Ca atom of CD4 and are shown at
the far left, along with the corresponding gp120
residue. The columns in this panel, from left to
right, denote distances in A˚ from the Ca of
CD4 Phe43, residue names, residue numbers,
and atom names. Difference distance matrices
composed of these cavity atoms were calculated
for unliganded YU2 gp120 and for gp120 com-
plexes with CD4, M48U1, and M48U7. Each i,j
matrix element shows the distance between atom i
and atom j in the first specified structure minus the
distance between the same atoms in the second
specified structure. The difference distance matrix
was quantified by mean difference distances,
and is shown for each comparison. Physical and
chemical properties of the gp120 Phe43-cavity
properties are summarized in Figure S3.
ghts reserved
Figure 5. Ligand-Induced Motion in the gp120 Phe43 Cavity
A cross-section of gp120 is shown as a transparent gray surface. Phe43 cavity atoms are shown as spheres, and the corresponding residues as sticks. Distance-
sorted difference distance matrices of the gp120 Phe43 cavity bound to the different ligands, shown in Figure 4, were used to calculate net motion at each cavity
atom. The cavity atoms were colored with a yellow-white-magenta gradient, where yellow represents the least motion and magenta represents the highest
differences between gp120 bound to CD4 (yellow) and 17b IgG versus unliganded gp120 (A), gp120 bound to M48U1 (red and green) versus unliganded gp120
(B), gp120 bound to M48U1 versus gp120 bound to CD4 and 17b IgG (C), gp120 bound to M48U7 (red and cyan) versus unliganded gp120 (D), and gp120 bound
to M48U7 versus gp120 bound to CD4 and 17b IgG (E). Analysis of the Phe43-cavity volume is shown in Figure S4.
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Cocrystal Structure of HIV-1 gp120 with M48U1miniproteins. These findings are consistent with published
studies showing that M48 is the closest mimic of CD4 (Stricher
et al., 2008) and that M47-bound gp120 deviates from the
CD4-bound structure around the ligand-binding site. We also
found that M47- and M48-bound states of the Phe43 cavity are
more similar to each other than they are to the Phe43 cavity
bound to either M48U1 or M48U7, and that the differences are
highest in magnitude at the deeper regions of the Phe43 cavity
(R13 A˚ from the Ca of 23M48U1), where U1 and U7 inserts
make additional contacts unexplored by either M48 or M47 (Fig-
ure 6; Figure S5).
Taken together, these results show that by inserting flexible
moieties into the Phe43 cavity, M48U1 and M48U7 induce a
Phe43-cavity conformation in core gp120 that is very close to
its ground-state conformation. This state is similar to, but distinct
from, the conformation the cavity assumes when core gp120
binds the CD4 receptor. Further, these analyses show that the
Phe43 cavity is malleable and can adapt its conformation to fit
an incoming ligand. Despite this malleability, the fact that the
various CD4-mimetic miniproteins have different affinities sug-Structure 21, 10gests that recognition of the ground state appears to be substan-
tially more favorable energetically than recognition of slightly
altered conformations.
HIV-1 Neutralization by M48U1 and M48U7
To understand the effect of M48U1 binding to the HIV-1 trimeric
spike, we assessed its ability to neutralize HIV-1, and compared
it to HIV-1 neutralization by sCD4, M48, M47, and M48U7 (Fig-
ure 7; Figure S6; Table 3; Table S3). We tested a panel of 24
pseudoviruses (Figure 7A; Table 3), selected from different
clades, for their susceptibility to be neutralized by either
M48U1 or M48U7. M48U1 neutralized 20 of the 24 isolates
(83%), with a geometric half-maximal inhibitory concentration
(IC50) mean of 0.39 mg/ml. In comparison, M48U7 neutralized
only 67% of the 24 isolates tested, with a geometric IC50 mean
of 5.18 mg/ml. M48U1 was also shown to be a better neutralizer
than all other currently known CD4-mimetic miniproteins of this
class (Van Herrewege et al., 2008).
For a more comprehensive estimate of its neutralization effi-
cacy, M48U1 was tested in an expanded panel of 180 HIV-118–1029, June 4, 2013 ª2013 Elsevier Ltd All rights reserved 1025
Figure 6. Comparison of Phe43 Cavity Conformation between Different CD4-Mimetic Miniproteins
Distance-sorted difference distancematrices of gp120were constructed using the same set of atoms as in Figure 4. Difference distancematrices were calculated
to compare Phe43-cavity conformations of gp120 bound to CD4-mimetic miniproteins M48, M47, M48U1, and M48U7, relative to each other. Each i,j matrix
element shows the distance between atom i and atom j in the first specified structure minus the distance between the same atoms in the second specified
structure. The difference distance matrix was quantified by the overall mean of the difference distances, and is shown for each comparison. Structural changes in
the Phe43-cavity conformation upon binding to different cavity-filling ligands are shown in Figure S5.
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Cocrystal Structure of HIV-1 gp120 with M48U1isolates representative of circulating Tier 1 and Tier 2 viruses.
M48U1 neutralized all isolates tested, except viruses from clade
A/E, with 90% overall breadth and geometric IC50 mean of
0.13 mg/ml (Figure 7; Table 3). In comparison, CD4 neutralizes
a similar HIV-1 panel with 79% breadth (Table 3; Figure S6)
and the CD4-binding site broadly neutralizing antibody VRC01
neutralizes HIV-1 with 91% breadth (Wu et al., 2010).
M48U1 neutralized all viruses tested other than isolates
belonging to clade A/E, a clade prevalent in Central Africa and
Southeast Asia. In addition, none of the clade A/E viruses tested
in this study were neutralized by M48U7. All clade A/E viruses1026 Structure 21, 1018–1029, June 4, 2013 ª2013 Elsevier Ltd All ritested had His at position 375, whereas all of the other HIV-1
clades tested contain the canonical Ser at position 375. Clade
A/E CA10.3, harboring a Ser375, was shown to be efficiently
neutralized by M48U1 (Van Herrewege et al., 2008). As inferred
from the structure of HIV-1 clade A/E 93Th057 gp120 (PDB ID
3TGT) (Kwon et al., 2012), His375 partially fills the Phe43 pocket,
thereby hindering access by the U1 and U7 moieties, allowing
the virus to resist a cavity-penetrating ligand yet remaining entry
competent by retaining binding to CD4, which only accesses the
mouth of the Phe43 pocket. In addition, S375R/N mutations
have been implicated in viral resistance to M48U1 (Gruppingghts reserved
Figure 7. HIV-1 Neutralization by CD4-
Mimetic Peptides M48U1 and M48U7
Neutralization profiles of M48U1 and M48U7
depicted with 24-isolate dendrograms (A) and of
M48U1 depicted with a 180-isolate dendrogram
representative of circulating HIV-1 Tier 1 and Tier 2
viruses (B). Neutralization IC50 values are tabulated
in Table S3. Neutralization dendrograms of sCD4,
M48, and M47 are shown in Figure S6. The
molecular weights of M48U1 and M48U7 are
3,048 Da and 3,038 Da, respectively.
Structure
Cocrystal Structure of HIV-1 gp120 with M48U1et al., 2012), consistent with the substrate-binding-envelope
hypothesis for drug design from Schiffer and colleagues
(Prabu-Jeyabalan et al., 2002), which postulates that inhibitors
that venture out of the envelope defined by natural susbtrates
are more susceptible to developing viral resistance under selec-
tive pressure of the inhibitor (King et al., 2004). Viral resistance to
ligands that access the inner recesses of the Phe43 pocket when
a bulky amino acid is placed at position 375 of gp120 has been
reported earlier for the nitrobenzoxadiazole class of compounds
(Kwon et al., 2012).
DISCUSSION
In this study, we have compared the gp120 Phe43 cavity
conformation in unliganded and CD4-bound core gp120 with
its conformation when bound to two flexible ligands of differing
chemistry that insert into this cavity. Although the ligands
varied in their respective ability to neutralize HIV-1, the confor-
mation of the Phe43 cavity in both cases resembled the unli-
ganded conformation of core gp120 more than the CD4-bound
conformation. Analysis of the affinities of the various CD4-
mimetic miniproteins, as well as of their recognized or induced
Phe43-cavity conformations, suggests that deviations of the
Phe43 cavity from the presumed ground state require substan-
tial energy. Only by optimizing a combination of chemistry,
Phe43-cavity filling, and complementary shape can the poten-
tial of the Phe43 cavity be realized—in this case by near-pan-
neutralization of HIV-1 and by a gp120 affinity for M48U1 of
0.015 nM.
CD4 makes a functionally critical interaction with the HIV-1
envelope, yet soluble CD4 only neutralizes HIV-1 moderately.
This is believed to be related to ‘‘conformational masking’’, the
requirement of conformational change of the viral spike to permit
CD4 binding, a requirement that trades CD4 affinity in the mono-
meric gp120 context for induction of the CD4-bound state in the
viral spike (Kwong et al., 2002). Two prior mechanisms have
been identified for CD4-binding-site ligands that nevertheless
achieve broad and potent HIV-1 neutralization: (1) Avidity—
multivalent versions of CD4 that are able to engage more than
one gp120 on the viral spike potently neutralize diverse strains
of HIV-1 (Arthos et al., 2002; Trkola et al., 1995), presumably
by spreading the energy required to change spike conformation
over several binding sites; (2) Avoiding conformation change—
antibody VRC01 is able to bind without inducing conformational
changes in the viral spike, allowing this antibody to neutralizeStructure 21, 10>90% of circulating HIV-1 isolates (Zhou et al., 2010). Here, we
focus on a third mechanism: optimization of the interaction of
the CD4-binding-site ligand with the interfacial Phe43 cavity. In
particular, we show that a CD4-mimetic ligand that gains affinity
by optimizing contacts in the Phe43 cavity can effect broad and
potent HIV-1 neutralization. This observation that high-affinity
binding can overcome the restrictions imposed by conforma-
tional masking may have important implications for neutraliza-
tion at the CD4-binding site of the HIV-1 envelope. It may be
possible to combine this third mechanism with the two identified
previously. A multimeric M48U1, for example, might have higher
potency than monomeric M48U1. Chemical modifications of a
Phe43Cys variant of CD4 have also been explored (Xie et al.,
2007). Also, recent studies have shown that engaging the
gp120 Phe43 cavity can lead to enhanced neutralization by
CD4-binding-site antibodies (Diskin et al., 2011). Thus, although
engagement of the Phe43 cavity may lead to a conformational
change of the HIV-1 envelope, our results demonstrate that opti-
mizing ligand fit in the Phe43 cavity can nonetheless lead to
potent, near-pan-neutralization of HIV-1. Induction of conforma-
tional change further allows the possibility of combining these
potent inhibitors with entry inhibitors that target the CD4i site
of coreceptor binding on gp120 (Acharya et al., 2011; Lagenaur
et al., 2010) or with inhibitors that target transient viral-envelope
intermediates farther downstream in the HIV-1 entry pathway
(Chen et al., 2002; Reeves et al., 2005).
In summary, our studies provide a structural explanation for
the broad and potent neutralization by the CD4-mimeticminipro-
tein M48U1. They show that achieving optimal fit to the Phe43
cavity can be an effective means of enhancing the neutralization
capability of a CD4-binding-site ligand. These results provide
frameworks, both mechanistic and structural, for optimizing
the interaction of CD4-binding-site ligandswith the Phe43 cavity,
a conserved site of HIV-1 vulnerability and a proven target for
HIV-1 neutralization.EXPERIMENTAL PROCEDURES
Synthesis of CD4-Mimetic Miniproteins, gp120 Expression, and
Purification
M48U1, M48U7, M48, and M47 were synthesized by solid-phase methods, as
described elsewhere (Martin et al., 2003). The concentrations of the peptides
in solution were determined by hydrochloric acid hydrolysis followed by amino
acid analysis. HIV-1 clade B YU2 gp120 coree (Kwon et al., 2012) was ex-
pressed, purified, and deglycosylated as previously described (Kwon et al.,18–1029, June 4, 2013 ª2013 Elsevier Ltd All rights reserved 1027
Structure
Cocrystal Structure of HIV-1 gp120 with M48U12012). Complexes with M48U1 and M48U7 were prepared following methods
described in the Supplemental Experimental Procedures.
Crystallization, X-RayDataCollection, StructureDetermination, and
Refinement of CD4-Mimetic Miniproteins in Complex with HIV-1
gp120
Crystallization of miniprotein-gp120 complexes and data collection are
described in the Supplemental Experimental Procedures, as are data integra-
tion and scaling, structure solution, refinement, and analysis.
Assessment of HIV-1 Neutralization
HIV-1 neutralization was measured using single-round-of-infection HIV-1
Env-pseudoviruses and TZM-bl target cells using protocols described in the
Supplemental Experimental Procedures.
Surface Plasmon Resonance
Experiments were carried out on a Biacore 3000 or Biacore T200 instrument
(GE Healthcare) using protocols described in the Supplemental Experimental
Procedures.
ACCESSION NUMBERS
Atomic coordinates and structure factors have been deposited in the Protein
Data Bank with PDB IDs 4JZW and 4JZZ for gp120-M48U1 in the P212121
and C2221 crystal forms, respectively, and 4K0A for gp120-M48U7.
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